Physician profile
Frederick E Rushford
NPI 1366440265
$17,657.97
in general payments reported to CMS, 2019-2025
60 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,181 · 2020: $3,039 · 2021: $3,193 · 2022: $2,949 · 2023: $1,786 · 2024: $1,727 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,273 · Education: $22.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,272.57 |
| Education | $22.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,513.71 | 2019-2023 | Farxiga |
| Radius Health, INC. | $1,451.81 | 2019-2025 | Tymlos |
| Novo Nordisk INC | $1,360.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $1,253.99 | 2019-2023 | |
| Lilly USA, LLC | $1,093.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $989.83 | 2019-2025 | Evenity, Prolia, Prolia |
| Dexcom, INC. | $825.85 | 2019-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $811.04 | 2019-2024 | Tirosint, Licart, Licart |
| Abbvie INC. | $749.51 | 2019-2025 | |
| Corcept Therapeutics | $610.78 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $536.21 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $470.45 | 2019-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $468.65 | 2019-2023 | |
| Mannkind Corporation | $414.11 | 2020-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.67 | 2019-2024 | Jardiance |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $351.86 | 2019-2021 | |
| Esperion Therapeutics, INC. | $336.89 | 2020-2023 | Nexletol |
| Antares Pharma, INC. | $325.58 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Novartis Pharmaceuticals Corporation | $292.54 | 2022-2025 | |
| Medicure Pharma INC. | $249.65 | 2020-2021 | |
| Tolmar, INC. | $233.84 | 2023-2025 | Jatenzo |
| Abbott Laboratories | $232.98 | 2019-2022 | |
| Clarus Therapeutics INC. | $231.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $215.97 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $215.27 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.21 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $188.72 | 2025 | Isturisa |
| Endo Pharmaceuticals INC. | $137.92 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $127.73 | 2022-2024 | Livalo, Seglentis |
| Alexion Pharmaceuticals, INC. | $105.66 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $103.87 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $98.82 | 2019-2022 | |
| Almatica Pharma LLC | $98.74 | 2025 | Teriparatide |
| Genzyme Corporation | $90.00 | 2019 | |
| Horizon Therapeutics Plc | $82.66 | 2021-2023 | Tepezza |
| Insulet Corporation | $55.83 | 2019-2025 | Omnipod |
| Verity Pharmaceuticals INC. | $55.83 | 2024 | Tlando |
| Zealand Pharma US, INC. | $55.28 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $54.22 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $48.99 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $48.15 | 2023-2025 | Contrave |
| Eisai INC. | $45.83 | 2019 | |
| Shire North American Group INC | $45.60 | 2019 | |
| Cequr Corporation | $42.49 | 2022-2024 | Cequr Simplicity |
| Vivus LLC | $37.38 | 2019-2023 | Pancreaze |
| Valeritas, INC. | $35.80 | 2019 | |
| Acerus Pharmaceuticals Corporation | $29.15 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $24.46 | 2019-2022 | |
| Halozyme INC | $23.69 | 2023 | |
| Kyowa Kirin, INC. | $23.65 | 2024 | Crysvita |
| Beta Bionics, INC. | $21.35 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Agepha Pharma Fz LLC | $20.57 | 2024 | Lodoco |
| Nevro Corp. | $17.82 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.61 | 2019 | |
| Avvisto Therapeutics, LLC | $16.23 | 2025 | Cycloset |
| Pfizer INC. | $16.00 | 2022 | |
| Medtronic Minimed, INC. | $15.77 | 2019 | |
| Embecta Corp. | $14.60 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Medtronic, INC. | $12.35 | 2022 | |
| Lifescan, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Rushford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.